Clinical Trial Update: A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a nucleoside-sparing regimen of atazanavir/ritonavir/efavirenz for HIV infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Norvir (ritonavir)
• REYATAZ (atazanavir)
• Sustiva (efavirenz)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 3 | Status: COMPLETED